Welcome : Guest

Viking Therapeutics, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Viking Therapeutics, Inc., which is principally a Clinical-Stage Biopharmaceutical Company. Illustrated with 85 tables, the report showcases the company's key markets and market position as against its competitors operating in the industry.

Code: PCP-65690
Price: $3500
Company Type: Public
Pages: 88
Date: January 2017
Market Data Tables: 85

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Diabetes......4
Table 1: Diabetes Market by Region Worldwide (2015) - Percentage Share Breakdown for Africa, Europe, Middle East & North Africa, North America & Caribbean, Southeast Asia, and Western Pacific......4
Table 2: Diabetes Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Insulin Type‐1 Diabetes, Insulin Type‐2 Diabetes, Dipeptidyl Peptidase 4, (DPP4), Glucagon-like Peptide-1 (GLP‐1), Dipeptidyl Peptidase 4, (DPP4) + Biguanide, and Others* (includes Sodium-Glucose Co-Transporter-2 (SGLT2), Biguanide, Sulfonylurea, Alpha-Glucosidase Inhibitors, Peroxisome Proliferator-Activated Receptor (PPAR)......5
Table 3: Diabetes Care Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Human Insulins, Modern Insulins, Victoza, and Others......6
Table 4: Type-II Diabetes Treatments Market Worldwide (2015-2020) in US$ Million......7
Table 5: Type II Diabetes Market by Treatment Worldwide (2015) - Percentage Share Breakdown by Value for DPP-IV Inhibitors, GLP-1 Agonists, SGLT-2 Inhibitors and Thiazolidinediones......8
Table 6: Type II Diabetes Market by Insulin Treatment Worldwide (2015) - Percentage Share Breakdown by Value for Diet and Exercise Only, Insulin and Orals and Insulin Only......9
Table 7: Diabetes Healthcare Market by Category in the US (2015) - Percentage Share Breakdown by Value for Anti -Diabetic Agents & Supplies, Doctor Office Visits, Hospital Care, Nursing/Residential Facility Stays, Prescription Medication, and Others......10
Table 8: Diabetes Market by Type in the US (2015) - Percentage Share Breakdown for Insulin Pumps, and Multiple Daily Injections......11
Table 9: Diabetes Market by Type in the US (2015) - Percentage Share Breakdown by Value for Type 1, and Type 2......12
Table 10: No. of Diabetes Patients by Medication in the US (2015) - Percentage Share Breakdown for Insulin and Oral Medication, Insulin Only, No Medication, and Oral Medication Only......13
Diabetes Drugs......14
Table 11: Diabetes Drug Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for DPP-4 Inhibitor, GK Activator, GLP-1 Agonist, GPCR Agonist, IL- Receptor Antagonist, Insulin Analogue, PPAR Agonist, SGLT-2 Inhibitor, and Others......14
Table 12: Diabetes/Metabolic Drugs Market by Category Worldwide (2015) - Percentage Breakdown by Value Sales for DPP-IV Inhibitors, Glitazones, GLP-1 Analogs, Insulins, Sulfonylureas, and Others......15
Table 13: Anti-Diabetic Drug Market by Treatment Class Worldwide (2015) - Percentage Share Breakdown by Value for Diet & Exercise, Incretion, Insulin and Oral Anti-Diabetic......16
Table 14: Antidiabetes Molecules Market by Drug Worldwide (2015) - Percentage Share Breakdown by Value for Metformin, Sulfonylureas, Thiazolidin Ediones and Others......17
Table 15: Anti-Diabetic Drugs Market in China (2015-2020) in RMB Million......18
Table 16: Diabetic Drugs Market by Category in China (2015) - Percentage Share Breakdown by Value for Biguanides, Glinide, Insulin, Sulfonylureas, α-glucosidase Inhibitor, and Others......19
Table 17: Anti-Diabetic Drugs Market by Category in China (2015) - Percentage Share Breakdown by Value for Insulin Drugs and Non-Insulin Drugs......20
Table 18: Diabetes Drugs Market by Product Category in China (2015) - Percentage Share Breakdown by Value for Acarbose, Insulin, Melbine, and Other Diabetes Drugs......21
Table 19: Diabetic Drugs Market by Category in the US (2015) - Percentage Share Breakdown by Value for DPP-IV & SGLT-2, GLP-1, Insulins, and Others......22
Table 20: Diabetic Drugs Market by Non-Insulin Therapy in the US (2015) - Percentage Share Breakdown by Volume for Biguanides, DPP-4 Inhibitor, Human GLP-1 Analogs, SGLT-2 Inhibitor, Sulfonylureas, and Others......23
Table 21: Oral Diabetes Medicine Market in the US (2015) - Percentage Share Breakdown by Value Sales for Dipeptidyl Peptidase-4 (DPP4), Metformin, Sulfonylureas, and Others......24
Non-Insulin Anti-Diabetic Drugs......25
Table 22: Non-Insulin Anti-Diabetic Drugs Market by Product in China (2015) - Percentage Share Breakdown by Value for Biguanides, Glucosidase Inhibitors, Nateglinide, Sulfonylurea and Others......25
Diabetic Macular Edema (DME)......26
Table 23: Diabetic Macular Edema (DME) Market by Drug Treatment Worldwide (2015) - Percentage Share Breakdown by Volume for Avastin, Laser Photocoagulation, Lucentis 0.3 mg, Steroids and Others......26
Table 24: Diabetic Macular Edema (DME) Anti Vascular Endothelial Growth Factor (VEGF) Market by Segment in the US (2015) - Percentage Share Breakdown by Volume for Avastin, Lucentis and Others......27
DPP-4 Inhibitors......28
Table 25: DPP-4 Inhibitors Market by Product Category Worldwide (2015) - Percentage Share Breakdown by Value for Galvus & Galvumet (Novartis), Januvia & Janumet (MRK), Nesina & Kezano (Takeda), Onglyza & Kombiglyze (AZN/BMY) and Tradjenta & Jentadueto (BI/Lilly)......28
Table 26: DPP-4 Inhibitors Market in China (2015-2020) in RMB Million......29
Table 27: DPP-4 type Diabetes Drugs Market in Japan (2015) in Yen Million......30
Table 28: DPP-4 Inhibitors (Fixed Dose) Market by Product Category in Korea (2015) - Percentage Share Breakdown by Value for Galvusmet, Janumet, Janumet XR, Kombiglyze, Trajenta Duo and Zemimet......31
Table 29: DPP-4 Inhibitors (Non-fixed Dose) Market by Product Category in Korea (2015) - Percentage Share Breakdown by Value for Januvia, Nesina, Tradjenta, Zemiglo, and Others......32
Table 30: DPP-4 Inhibitors Market by Prescription in the US (2015) - Percentage Share Breakdown by Volume for Janumet (Sitagliptin + Metformin), Januvia (Sitagliptin), Kombiglyze XR (Saxagliptin + Metformin), Onglyza (Saxagliptin), and Others......33
Table 31: DPP-4 Inhibitors Market in the US (2015) in No. of Prescriptions......34
Cancer Drugs......35
Table 32: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......35
Table 33: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......36
Cancer Market......37
Table 34: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others*......37
Table 35: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......38
Table 36: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......39
Table 37: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......40
Table 38: Hereditary Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......41
Table 39: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......42
Table 40: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......43
Table 41: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......44
Cancer Patients......45
Table 42: Breast Cancer Diagnoses by Hospital Type in the US (2015) - Percentage Share Breakdown by Volume for Community, Comprehensive, Teaching and Research, and Others......45
Table 43: No. of Colorectal Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......46
Table 44: No. of Invasive Breast Cancer Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......47
Table 45: No. of Primary Liver Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......48
Table 46: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Imbruvica PCYC, Rituxan, Gazyva ROG, and Others......49
Table 47: No. of Cutaneous Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......50
Table 48: No. of Ocular Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......51
Table 49: Female Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Lung, Breast, Colon, Rectum and Anus, Intestine, Liver, and Others......52
Table 50: Male Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Colon, Colon, Rectum and Anus, Intestine, Liver, Lung, and Others......53
Table 51: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......54
Table 52: No. of Chronic Lymphocytic Leukemia (CLL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......55
Table 53: No. of Cancer Patients by Type in the US (2015) - Percentage Market Share Breakdown for Colorectal Cancer (CRC), Melanoma, Non-Squamous Non-Small-Cell Lung Cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), and Squamous Non-Small-Cell Lung Cancer (NSCLC)......56
Table 54: Number of Cancer Patients by Type in the US (2015) - Percentage Share Breakdown by Volume for Bladder Cancer, Breast Cancer (Female), Colon and Rectum Cancer, Endometrial Cancer, Kidney and Renal Pelvis Cancer, Lung and Bronchus Cancer, Melanoma of the Skin, Non-Hodgkin Lymphoma, Prostate Cancer, and Thyroid Cancer......57
Table 55: No. of Cancer Patients Death by Type in the US (2015) - Percentage Share Breakdown for Breast, Colorectal, Lung, Melanoma, and Prostate......58
Table 56: New Patients with Cancer by Site in the US (2015) - Percentage Market Share Breakdown by volume for Colorectal, Lung and Bronchus, Melanoma, Pancreas, and Others......59
Table 57: Number of Cancer Patients by Type Worldwide (2015) - Percentage Share Breakdown by Volume for Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Non-Hodgkin lymphoma, Oesophagus, Prostate, and Stomach......60
Table 58: No. of Bladder Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Invasive Patients, and Non-Invasive Patients......61
Table 59: No. of Invasive Breast Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......62
Table 60: New Patients with Cancer in Stage 3/4 by Site in the US (2015) - Percentage Market Share Breakdown by Volume for Colorectal, Lung and Bronchus, Pancreas and Others......63
Table 61: No. of Solid Cancer Tumor Patients by Type Worldwide (2015) - Percentage Share Breakdown for Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer......64
Table 62: No. of Non Small Cell Lung Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I, Stage II-III, Stage III-IV, and Undiagnozed......65
Cervical Cancer......66
Table 63: Cervical Cancer Market by HPV Type in England (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 33, HPV 45, and Others......66
Table 64: Cervical Cancer Market by HPV Type in Europe (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 31, HPV 33, and Others......67
Hematological Cancer......68
Table 65: Hematological Cancer by Category Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin’s Lymphoma (NHL)......68
Skin Cancer......69
Table 66: Skin Cancer by Type Worldwide (2015) - Percentage Market Share Breakdown by Volume for Basal Cell Carcinomas, Melanoma, and Squamous Cell Carcinomas......69
Cancer-Associated Mucositis......70
Table 67: Cancer-Associated Mucositis Market by Activity Worldwide (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Head and Neck, Non-Small Cell Lung cancer and Others......70
Chronic Myelogenous Leukemia (CML)......71
Table 68: Chronic Myelogenous Leukemia (CML) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for Asia-Pacific, Canada, European Union, Japan, USA, and Others......71
Multiple Myeloma......72
Table 69: Multiple Myeloma by Age Group Worldwide (2015) - Percentage Share Breakdown by No. of New Cases for 45-54, 55-64, 65-74, 75-84, >84, and Others......72
Table 70: Multiple Myeloma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Kyprolis AMGN, Pomalyst CELG, Revlimid CELG, Thalomid CELG, and Velcade TKD/JNJ......73
Table 71: Market Shares of Leading Diabetes Care Companies Worldwide (2014) - Percentage Breakdown by Value Sales for Bristol-Myers Squibb (Incl Amylin), Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk A/S, Sanofi S.A. and Others......74
Table 72: Market Shares of Leading Diabetes Drugs Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Sanofi S.A., and Others......75
Table 73: Market Shares of Leading Anti-Diabetic Drug Manufacturers in India (2014) - Percentage Breakdown by Value for Abbott Healthcare Pvt Ltd., Biocon Limited, Lupin Pharmaceuticals, Inc., MSD Pharmaceuticals Private Limited, Sanofi-Aventis Groupe, Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., and Others......76
Table 74: Market Shares of Leading DPP-4 Inhibitors Manufacturers by Value Sales Worldwide (2015) - Percentage Share Breakdown for Merck & Co., Inc. (Januvia/Janumet), Novartis AG (Galvus/Galvumet) and Takeda Pharmaceutical Co., Ltd. (Nesina/Kezano), and Others......77
Table 75: Market Shares of Leading DPP-4 Inhibitors for Treatment of Diabetes in Japan (2015) - Percentage Share Breakdown by Value for Equa, Glactiv, Januvia, Nesina, and Others......78
Table 76: Market Shares of Leading DPP-4 Drug Brands in China (2015) - Percentage Share Breakdown by Value for Galvus, Januvia, Onglyza, and Others......79
Table 77: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......80
Table 78: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......81
Table 79: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......82
Table 80: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......83
Table 81: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......84
Breast Cancer Drugs......85
Table 82: Market Shares of Leading Breast Cancer Drugs by Value Sales in China (2014) - Percentage Breakdown for Alkylating Agents, Antimetabolite, Antitumor Antibiotics, Antitumor Antihormone, Antitumor Botanicals, Monoclonal Antibodies, Targeted Small Molecule Agents, and Others......85
Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL)......86
Table 83: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......86
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......87
Table 84: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......87
Table 85: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Others......88